This revealed KRAS missense mutation rates of 1% in PTC and 41% in CRC; BRAF, 62% in PTC and 12% in CRC (missense or fusion); and NRAS, 8% in PTC and 4% in CRC (missense) (Fig. 1A). This evidence concerns the gene KRAS and colorectal carcinoma.